(b)

On November14, 2016, Dipexium Pharmaceuticals,Inc. (the Company) and David Garrett, the Companys Vice President, Finance and Corporate Development, mutually agreed to terminate Mr.Garretts employment agreement, effective as of November30, 2016, so that he may pursue other opportunities. The decision of the Company to terminate Mr.Garretts employment agreement was not the result of a disagreement between Mr.Garrett and the Company on any matter relating to the Companys financial condition or financial reporting. The Company and Mr.Garrett are finalizing the terms of his severance arrangement, which will be disclosed in a separate report on Form8-K once agreed upon.

2

SIGNATURE

Pursuant to the requireme nts of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

DIPEXIUM PHARMACEUTICALS,INC.

Date: November15, 2016

/s/ David P. Luci

Name:

David P. Luci

Title:

President and Chief Executive Officer

3

makes a similar move, sign up!

Other recent filings from the company include the following:

General statement of acquisition of beneficial ownership - Nov. 20, 2017
Dipexium Pharmaceuticals, Inc. Just Filed Its Quarterly Report: Loss per share Basic... - Nov. 9, 2017
Departure of Directors or Certain - Oct. 27, 2017

Auto Refresh

Feedback